Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae

Antimicrobial Agents and Chemotherapy - Tập 61 Số 6 - 2017
Lucy Cheng1, Brian Nelson2, Monica Mehta2, Nikhil Seval1, Sarah E. Park1, Marla J. Giddins1, Qiuhu Shi3, Susan Whittier4, Angela Gomez‐Simmonds1, Anne‐Catrin Uhlemann1
1Department of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA
2NewYork-Presbyterian Hospital, New York, New York, USA
3New York Medical College, Valhalla, New York, USA
4Department of Pathology and Cell Biology, Clinical Microbiology Laboratory, Columbia University Medical Center, New York, New York, USA

Tóm tắt

ABSTRACT In vivo induction of AmpC beta-lactamases produces high-level resistance to many beta-lactam antibiotics in Enterobacteriaceae , often resulting in the need to use carbapenems or cefepime (FEP). The clinical effectiveness of piperacillin-tazobactam (TZP), a weak inducer of AmpC beta-lactamases, is poorly understood. Here, we conducted a case-control study of adult inpatients with bloodstream infections (BSIs) due to Enterobacter , Serratia , or Citrobacter species from 2009 to 2015 to assess outcomes following treatment with TZP compared to FEP or meropenem (MEM). We collected clinical data and screened all isolates for the presence of ampC alleles by PCR. Primary study outcomes were 30-day mortality and persistent bacteremia at ≥72 h from the time of treatment initiation. Of 493 patients with bacteremia, 165 patients met the inclusion criteria, of which 88 were treated with TZP and 77 with FEP or MEM. To minimize differences between covariates, we carried out propensity score matching, which yielded 41 matched pairs. Groups only differed by age, with patients in the TZP group significantly older ( P = 0.012). There were no significant differences in 30-day mortality, persistent bacteremia, 7-day mortality, or treatment escalation between the two treatment groups, including in the propensity score-matched cohort. PCR amplification and sequencing of amp C genes revealed the presence of amp C in isolates with cefoxitin MICs below 16 μg/ml, in particular in Serratia spp., and demonstrated that these alleles were highly genetically diverse. Taken together, TZP may be a valuable treatment option for BSIs due to AmpC beta-lactamase-producing Enterobacteriaceae , diminishing the need for broader-spectrum agents. Future studies are needed to validate these findings.

Từ khóa


Tài liệu tham khảo

10.1128/CMR.8.4.557

CDC. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/drugresistance/threat-report-2013/.

10.1086/595011

10.1111/1469-0691.12719

10.1128/CMR.00036-08

10.1055/s-0034-1398387

10.1128/AAC.37.2.153

10.1128/JCM.43.6.2955-2958.2005

10.7326/0003-4819-115-8-585

10.1093/cid/cit395

10.1093/cid/ciu182

10.1097/PAT.0000000000000255

10.1186/s13756-017-0177-0

10.1128/AAC.47.6.1882-1886.2003

10.1128/JCM.40.6.2153-2162.2002

10.1080/00273171.2011.568786

10.1093/jac/dkn155

10.1093/jac/dkv346

10.1016/j.clinthera.2016.11.025

10.1101/gr.205245.116

CLSI. 2015. Performance standards for antimicrobial susceptibility testing. Twenty-fifth informational supplement, document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.

10.1016/0021-9681(87)90171-8

10.1086/420816

10.1378/chest.101.6.1644

Thông tin
Thông tin xuất bản

Antimicrobial Agents and Chemotherapy

Tập 61 Số 6

Thông tin tác giả